Abstract:e13508 Background: Murine double minute-2 (MDM2) has increasing clinic relevance as preclinical and early clinical evidences have showed that the MDM2 inhibitors are promising alternative treatments for patients with MDM2-amplified (-amp) and TP53-wild-type (-WT) tumors by preventing TP53 protein degradation. However, exploration into genomic landscape of MDM2/TP53 across various solid tumors in Chinese patients is still limited. Methods: Formalin-fixed, paraffin-embedded (FFPE) tumor samples were collected from 10010 Chinese patients with solid tumors and subjected to a clinical-grade next-generation sequencing (NGS)-based 450 gene panel testing carried out by a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. Genomic alterations (GAs) including single base substitutions, short and long insertion/deletions (Indels), copy number variations, gene fusions, and rearrangements were analyzed. Tumor mutational burden (TMB) was measured by a NGS algorithm. Results: Amplification of MDM2 occurred in 3.3% of Chinese patients. MDM2-amp was detected most frequently in soft tissue sarcoma (STS, 11.4 %), melanoma (10.3 %) and osteosarcoma (6.3 %). Notably, MDM2-amp was revealed to be mutually exclusive with TP53-mut in most tumor types other than esophageal carcinoma (93.9 %), head and neck carcinoma (68.4%) and ovarian carcinoma (50 %). Tumors with highest frequencies of MDM2-amp/ TP53-WT were melanoma (100%), osteosarcoma (100%) and urothelial carcinoma (100 %). The most common co-altered genes accompanied with MDM2-amp were FRS2 (84%), CDK4 (38%), EGFR (26%), TP53 (17%) and GLI1 (14%). 82.8% patients who had one or more co-alterations potentially targetable with either FDA-approved or investigational agent. Moreover, TMB of MDM2-amp tumors were significantly lower than that of MDM2-WT and MDM2-mutation (-mut) tumors (median TMB: 3.1 vs. 4.6 vs. 10.8, p < 0.001 respectively). Conclusions: MDM2 amplification was found in 3.3% of 10010 Chinese cancer patients, 83.4% of whom harbored wild-type TP53 that were potentially responsive to MDM2 inhibitors. In addition, 82.8% of the patients with MDM2-amp harbored genomic co-alterations and were potentially therapy targetable. This study provided insights into identifying patients who might potentially benefit from anti-MDM2 therapies.

SNIP 1 Recruits TET 2 to Regulate c-MYC Target Genes and Cellular DNA Damage Response

SNIP1 Recruits TET2 to Regulate C-Myc Target Genes and Cellular DNA Damage Response.

Identification of TET1⊣miR-22⊣CREB-MYC Signaling Reveals Potent Tumor-Suppressor Role of Mir-22 in Acute Myeloid Leukemia

Pharmacological Targeting of MYC-regulated IRE1/XBP1 Pathway Suppresses MYC-driven Breast Cancer

Tet2 Downregulation Promotes Aml Cell Proliferation Via Pim-1 Expression

Comprehensive Profiling of MDM2/TP53 Genomic Aberration in Chinese Patients with Diverse Malignancies.

Tet1 Regulates Dna Replication Through Targeting of Minichromosome Maintenance Genes

Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

SMYD2 inhibition-mediated hypomethylation of Ku70 contributes to impaired nonhomologous end joining repair and antitumor immunity

COP 9 signalosome subunit 6 promotes tumorigenesis through stabilization of MDM 2

KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming

The deacetylation-phosphorylation regulation of SIRT2-SMC1A axis as a mechanism of antimitotic catastrophe in early tumorigenesis

Perturbing TET2 condensation promotes aberrant genome-wide DNA methylation and curtails leukaemia cell growth

Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer

eins SUN 1 and SUN 2 Play a Prominent Role in the DNA Damage Response

Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.

Pharmacoproteomics Identifies PLK1 As Vulnerability for Aggressive B-Cell Lymphomas

Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability

MYC shapes ER-mitochondria calcium transfer by directly targeting : implications for MYC-induced safeguard mechanisms and cancer

KMT5A-methylated SNIP1 promotes triple-negative breast cancer metastasis by activating YAP signaling